In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 1 to 17 of 17

Sort by

Keyword or reference number: breast`Remove $Keyword or reference number: breast filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]	Technology appraisal guidance	TBC
Advanced breast cancer: diagnosis and management (Partial update)	NICE guideline	29 May 2026
Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]	Technology appraisal guidance	TBC
Breast cancer guidelines	NICE guideline	TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]	Technology appraisal guidance	TBC
Familial Breast Cancer: initial assessment and genetic testing (update)	NICE guideline	22 April 2027
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]	Technology appraisal guidance	TBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]	Technology appraisal guidance	TBC
Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [TSID12194]	Technology appraisal guidance	TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]	Technology appraisal guidance	TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]	Technology appraisal guidance	TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]	Technology appraisal guidance	TBC
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women [ID1307]	Technology appraisal guidance	TBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401]	Technology appraisal guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]	Technology appraisal guidance	7 May 2026
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC

Results per page

10
25
50
All